In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in ...

Association of estrogen receptor status with survival outcomes in neuroendocrine carcinoma of the breast: A SEER Research Plus analysis (2010–2021). This is an ASCO Meeting Abstract from the 2026 ASCO ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...

Among men with cribriform-positive disease at radical prostatectomy, only those with grade group 3 or higher disease or pT3b likely need adjuvant or early salvage treatment. Among men found to have ...

Recent approvals of trastuzumab deruxtecan (T-DXd; Enhertu) in early HER2-positive breast cancer have created new questions about its optimal use in the neoadjuvant and adjuvant settings. Rugo: Let's ...

Please provide your email address to receive an email when new articles are posted on . Women with cardiovascular disease may have a higher risk for advanced breast cancer diagnosis. Researchers ...